Cost Effective Treatment for Dually Diagnosed Homeless

This study has been completed.
Sponsor:
Information provided by:
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00368524
First received: August 23, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted
  Purpose

This randomized controlled trial examined whether an abbreviated treatment using abstinence contingency management for housing and work/training (CM, n=103) with cocaine dependent, non-psychotic, dually diagnosed homeless persons, would show non-inferior outcomes compared to the full treatment (CM+, n=103). It was hypothesized that CM+ would show superior abstinence and retention outcomes, but that CM, with components derived from previously effective behavioral day treatment, would obtain non-inferior outcomes, defined as 75% or more of those observed for the full treatment (CM+) during active treatment months 1-6. The CM+ included all CM components but added behavioral day treatment that included voucher reinforcement of $7.50-15.00, for objective weekly therapeutic goal attainment in five domains of functioning: drug dependence, homelessness, unemployment, non-drug related recreational activities, and behavioral, health, or mental health problems. Abstinence was assessed by observed urine specimen collection and weekly testing weeks 1-52, and randomly, bi-monthly for months 13-18. Abstinence, homelessness, employment and other outcomes were also assessed at baseline, 2, 6, 12, and 18 months.


Condition Intervention
Cocaine Dependence
Mental Disorder
Homelessness
Unemployment
Behavioral: contingency management and behavioral day treatment

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Cost Effective Treatment for Dually Diagnosed Homeless

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • abused drug abstinence measured by observed urine specimen testing weeks 1-52, and bimonthly months 13-18

Secondary Outcome Measures:
  • abstinence, housing, employment and other outcomes at 0, 2, 6, 12 and 18 months.

Estimated Enrollment: 160
Study Start Date: November 2001
Estimated Study Completion Date: November 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: McKinney Act criteria for homelessness; DSM IV diagnosis for Cocaine Dependence; self-reported use within the last 2 weeks; psychological distress indicated by score of 70 on 1 or more Brief Symptom Inventory scales; willingness to participate; no plans to move from Birmingham area for 18 months;

-

Exclusion Criteria: cognitive impariment precluding informed consent; requiring immediate inpatient medical treatment

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00368524

Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Principal Investigator: Jesse B. Milby, Ph.D. ABPP University of Alabama at Birmingham
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00368524     History of Changes
Other Study ID Numbers: F920822004, 1R01DA11789
Study First Received: August 23, 2006
Last Updated: August 23, 2006
Health Authority: United States: Institutional Review Board

Keywords provided by University of Alabama at Birmingham:
cocaine dependence
mental disorder
dual diagnoses
homelessness

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Cocaine-Related Disorders
Schizophrenia and Disorders with Psychotic Features
Substance-Related Disorders
Chemically-Induced Disorders

ClinicalTrials.gov processed this record on August 28, 2014